Royalty Pharma (RPRX) News Today → Missed NVDA? Buy this AI stock NOW (From Chaikin Analytics) (Ad) Free RPRX Stock Alerts $26.64 +0.02 (+0.08%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 28 at 3:23 PM | msn.comWhy Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?May 28 at 7:10 AM | globenewswire.comRoyalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 MillionMay 27 at 4:47 PM | marketbeat.comS&CO Inc. Has $9.33 Million Position in Royalty Pharma plc (NASDAQ:RPRX)S&CO Inc. increased its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 31.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 332,110 shares of the biopharmaceutical company's stock after purchasing an additional 78,5May 26 at 4:48 AM | marketbeat.comJump Financial LLC Has $317,000 Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)Jump Financial LLC reduced its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 94.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 11,300 shares of the biopharmaceutical company's stock after seMay 25 at 8:14 AM | marketbeat.comNorges Bank Purchases Shares of 4,262,736 Royalty Pharma plc (NASDAQ:RPRX)Norges Bank acquired a new stake in Royalty Pharma plc (NASDAQ:RPRX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 4,262,736 shares of the biopharmaceutical company's stock, valued at approximately $119,7May 23, 2024 | markets.businessinsider.comHeart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts ObserveMay 22, 2024 | marketwatch.comCytokinetics Falls 10% on Royalty Pharma Transaction, Stock OfferMay 22, 2024 | msn.comCytokinetics to get up to $575M in funding from Royalty PharmaMay 22, 2024 | globenewswire.comRoyalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D PipelineMay 22, 2024 | marketbeat.comING Groep NV Invests $1.30 Million in Royalty Pharma plc (NASDAQ:RPRX)ING Groep NV purchased a new position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 46,200 shares of the biopharmaceutical company's stock, valued aMay 20, 2024 | marketbeat.comTrexquant Investment LP Has $12.15 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX)Trexquant Investment LP lifted its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 37.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 432,589 shares of the biopharmaceutical company's stock after purchasiMay 20, 2024 | investorplace.com7 Dividend Stocks to Buy at a 52-Week LowMay 19, 2024 | marketbeat.comKingsview Wealth Management LLC Makes New $1.28 Million Investment in Royalty Pharma plc (NASDAQ:RPRX)Kingsview Wealth Management LLC bought a new position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 45,573 shares of the biopharmaceutical company's stock, valued at approximately $1,280,000.May 18, 2024 | marketbeat.comRoyalty Pharma plc (NASDAQ:RPRX) Position Boosted by Panagora Asset Management Inc.Panagora Asset Management Inc. lifted its holdings in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 326.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 281,015 shares of the biopharmaceutical company's stock afMay 16, 2024 | marketbeat.comNational Bank of Canada FI Sells 79,441 Shares of Royalty Pharma plc (NASDAQ:RPRX)National Bank of Canada FI decreased its position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 69.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 34,872 shares of the biopharmaceutical company's stock after selMay 15, 2024 | marketbeat.comVictory Capital Management Inc. Reduces Holdings in Royalty Pharma plc (NASDAQ:RPRX)Victory Capital Management Inc. decreased its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 21.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 265,711 shares of the biopharmaceutical company's stock after selliMay 14, 2024 | marketbeat.comTorray Investment Partners LLC Increases Stake in Royalty Pharma plc (NASDAQ:RPRX)Torray Investment Partners LLC lifted its stake in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 22.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 505,740 shares of the biopharmaceutical company's stock after purchasing aMay 13, 2024 | finance.yahoo.comRoyalty Pharma to Present at Upcoming Investor ConferencesMay 12, 2024 | finance.yahoo.comHere's What Analysts Are Forecasting For Royalty Pharma plc (NASDAQ:RPRX) After Its First-Quarter ResultsMay 11, 2024 | finance.yahoo.comOnly Four Days Left To Cash In On Royalty Pharma's (NASDAQ:RPRX) DividendMay 11, 2024 | seekingalpha.comRoyalty Pharma: Solid Start Of The Year, Buy ConfirmedMay 11, 2024 | marketbeat.comRoyalty Pharma (NASDAQ:RPRX) Stock Rating Lowered by StockNews.comStockNews.com lowered Royalty Pharma from a "buy" rating to a "hold" rating in a research report on Friday.May 10, 2024 | marketbeat.comRoyalty Pharma (NASDAQ:RPRX) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPSRoyalty Pharma (NASDAQ:RPRX - Get Free Report) posted its earnings results on Thursday. The biopharmaceutical company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.96 by $0.02. Royalty Pharma had a net margin of 48.22% and a return on equity of 26.93%. The company had revenue of $568.00 million during the quarter, compared to the consensus estimate of $671.45 million. During the same period in the previous year, the firm posted $1.60 earnings per share.May 10, 2024 | msn.comRoyalty Pharma plc (NASDAQ:RPRX) Q1 2024 Earnings Call TranscriptMay 10, 2024 | uk.finance.yahoo.comQ1 2024 Royalty Pharma PLC Earnings CallMay 9, 2024 | finanznachrichten.deRoyalty Pharma plc: Royalty Pharma to Acquire Royalty Interest in Sanofi's FrexalimabMay 9, 2024 | markets.businessinsider.comRoyalty Pharma Beats Q1 Earnings and Revenue EstimatesMay 9, 2024 | investorplace.comRPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024May 9, 2024 | globenewswire.comRoyalty Pharma to Acquire Royalty Interest in Sanofi's FrexalimabMay 8, 2024 | marketbeat.comSwiss National Bank Has $33.52 Million Position in Royalty Pharma plc (NASDAQ:RPRX)Swiss National Bank decreased its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 2.6% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,193,200 shares of the biopharmaceutical company's stock after sMay 7, 2024 | marketbeat.comRussell Investments Group Ltd. Grows Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)Russell Investments Group Ltd. lifted its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 20.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 322,967 shares of the biopharmaceutical company's stoMay 4, 2024 | finance.yahoo.comRoyalty Pharma's (NASDAQ:RPRX) Dividend Will Be $0.21May 1, 2024 | marketbeat.comRoyalty Pharma plc (NASDAQ:RPRX) Shares Sold by New York State Common Retirement FundNew York State Common Retirement Fund lowered its stake in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 8.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 390,282 shares of the biopharmaceApril 27, 2024 | marketbeat.com33,091 Shares in Royalty Pharma plc (NASDAQ:RPRX) Bought by Aubrey Capital Management LtdAubrey Capital Management Ltd acquired a new position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 33,091 shares of the biopharmaceutical compApril 26, 2024 | marketbeat.comRoyalty Pharma plc (NASDAQ:RPRX) Shares Purchased by California Public Employees Retirement SystemCalifornia Public Employees Retirement System grew its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 5.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,136,899 shares of the biopApril 26, 2024 | marketbeat.comOverbrook Management Corp Has $6.17 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX)Overbrook Management Corp lessened its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 26.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 219,677 shares of the biopharmaceutical company'sApril 23, 2024 | marketbeat.comHandelsbanken Fonder AB Has $25.05 Million Stake in Royalty Pharma plc (NASDAQ:RPRX)Handelsbanken Fonder AB trimmed its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 4.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 891,918 shares of the biopharmaceutical coApril 22, 2024 | marketbeat.comSumitomo Mitsui Trust Holdings Inc. Reduces Stake in Royalty Pharma plc (NASDAQ:RPRX)Sumitomo Mitsui Trust Holdings Inc. lowered its position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 21.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,018,626 shares of the biopharmaceuticApril 20, 2024 | finance.yahoo.comRoyalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21April 19, 2024 | globenewswire.comRoyalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024April 19, 2024 | marketbeat.comRiver Road Asset Management LLC Purchases Shares of 154,639 Royalty Pharma plc (NASDAQ:RPRX)River Road Asset Management LLC purchased a new position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 154,639 shares of the biopharmaceutical coApril 18, 2024 | marketbeat.comRoyalty Pharma plc Plans Quarterly Dividend of $0.21 (NASDAQ:RPRX)Royalty Pharma plc (NASDAQ:RPRX) announced a quarterly dividend on Wednesday, April 17th. Investors of record on Friday, May 17th will be paid a dividend of 0.21 per share by the biopharmaceutical company on Friday, June 14th. This represents a $0.84 annualized dividend and a yield of 3.04%. The ex-dividend date of this dividend is Thursday, May 16th.April 17, 2024 | seekingalpha.comRoyalty Pharma declares $0.21 dividendApril 17, 2024 | finance.yahoo.comRoyalty Pharma Declares Second Quarter 2024 DividendApril 17, 2024 | globenewswire.comRoyalty Pharma Declares Second Quarter 2024 DividendApril 14, 2024 | nasdaq.comRelative Strength Alert For Royalty PharmaApril 14, 2024 | marketbeat.comNisa Investment Advisors LLC Purchases 68,900 Shares of Royalty Pharma plc (NASDAQ:RPRX)Nisa Investment Advisors LLC raised its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 1,129.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 75,000 shares of the biopharApril 12, 2024 | marketbeat.comRoyalty Pharma plc (NASDAQ:RPRX) Receives Average Rating of "Buy" from BrokeragesRoyalty Pharma plc (NASDAQ:RPRX - Get Free Report) has received a consensus recommendation of "Buy" from the four ratings firms that are currently covering the company, MarketBeat reports. Four research analysts have rated the stock with a buy rating. The average 12-month target price among analysApril 11, 2024 | investorplace.com3 Pharma Stocks to Sell in April Before They Crash & BurnApril 11, 2024 | marketbeat.comStockNews.com Upgrades Royalty Pharma (NASDAQ:RPRX) to BuyStockNews.com raised shares of Royalty Pharma from a "hold" rating to a "buy" rating in a report on Thursday. Get Royalty Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Missed NVDA? Buy this AI stock NOW (Ad)After Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in seven months. So if you currently own NVIDIA (NVDA)... Or were thinking of buying it in the weeks ahead... I urge you to review my recent interview with 50-year Wall Street legend Marc Chaikin. You can watch it here. RPRX Media Mentions By Week RPRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RPRX News Sentiment▼0.810.79▲Average Finance News Sentiment RPRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RPRX Articles This Week▼124▲RPRX Articles Average Week Get Royalty Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Jazz Pharmaceuticals News Today Perrigo News Today Corcept Therapeutics News Today Supernus Pharmaceuticals News Today Pacira BioSciences News Today Nektar Therapeutics News Today Omeros News Today Assembly Biosciences News Today Cumberland Pharmaceuticals News Today Regeneron Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RPRX) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersWARNING about the death of the U.S. dollar…Colonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersDigitizing the $11T commodities sector with one tiny stockResource Stock DigestBiggest Prediction of My 50-Year Career on Wall StreetChaikin AnalyticsHe Is Giving Away BitcoinCrypto Swap ProfitsElon’s New Device is About to Shock the WorldInvestorPlaceTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Royalty Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
